Journal of Pharmacovigilance

Aspects of Pharmacovigilance in Drug Safety

Sai Batchu^* Department of Medicine, Chulalongkorn University, Bangkok, Thailand
^*Correspondence: Sai Batchu, Department of Medicine, Chulalongkorn University, Bangkok, Thailand, Email:

Received: 01-Jul-2023, Manuscript No. JP-23-22706; Editor assigned: 03-Jul-2023, Pre QC No. JP-23-22706(PQ); Reviewed: 17-Jul-2023, QC No. JP-23-22706; Revised: 24-Jul-2023, Manuscript No. JP-23-22706(R); Published: 31-Jul-2023, DOI: 10.35248/2329-6887.23.11.439

About the Study

Pharmacovigilance is a critical component of modern healthcare systems, focusing on the systematic monitoring, assessment, and prevention of adverse effects and other safety-related issues associated with pharmaceutical products. This article explores key aspects of pharmacovigilance, including its significance, methods, challenges, and advancements in ensuring drug safety.

Pharmacovigilance, stemming from the etymological amalgamation constitutes a pivotal cornerstone within contemporary healthcare frameworks. It assumes a pivotal role by orchestrating the systematic surveillance, assessment, and mitigation of untoward effects and safety-related concerns accompanying medicinal products subsequent to their regulatory endorsement and subsequent market integration [1]. The sustained vigilance exercised over drug safety underscores its paramount significance in recognizing and attenuating latent risks that might have evaded identification during antecedent preclinical and clinical appraisal phases.

One of the fundamental aspects of pharmacovigilance involves the collection and analysis of data from various sources. Adverse event reports submitted by healthcare professionals, patients, and pharmaceutical companies are central to this process. These reports provide invaluable insights into real-world experiences and enable the identification of potential safety signals. Data mining techniques, including signal detection algorithms and disproportionality analysis, help to pinpoint unusual patterns or associations that warrant further investigation. Additionally, electronic health records, social media monitoring, and large healthcare databases contribute to a more comprehensive understanding of drug safety profiles [2-4].

Pharmacovigilance encounters several challenges that necessitate continuous refinement of its methodologies. Underreporting of adverse events remains a significant hurdle, as healthcare professionals and patients may be unaware of reporting mechanisms or reluctant to attribute events to medication use [5]. Developing countries often lack well-established pharmacovigilance systems, resulting in limited access to critical safety information. Furthermore, the complex interplay of various factors in adverse events, including patient characteristics, concomitant medications, and underlying diseases, complicates the causal attribution of observed effects [6].

Recent advancements in technology have revolutionized the field of pharmacovigilance. Natural Language Processing (NLP) algorithms have enabled the automated extraction of information from unstructured text, such as electronic health records and medical literature, enhancing the efficiency of data collection. Artificial Intelligence (AI) and Machine Learning (ML) techniques enable the identification of previously unrecognized safety signals by analyzing vast amounts of data for potential associations. Additionally, data linkage between disparate sources offers a more comprehensive perspective on the safety profiles of medications [7].

Pharmacovigilance is not confined to individual countries, as adverse events can have international implications. Global collaboration through organizations like the World Health Organization (WHO) fosters the exchange of safety information and promotes harmonized approaches to drug safety monitoring. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) [8,9], play a significant role in evaluating safety data and making informed regulatory decisions to protect public health.

In conclusion, pharmacovigilance is an indispensable component of modern healthcare systems, ensuring the ongoing assessment of drug safety post-approval. The systematic collection, analysis, and interpretation of safety data from diverse sources contribute to the early detection and management of adverse effects, thereby safeguarding patient wellbeing [10]. Despite challenges, continuous advancements in technology and global collaboration hold the promise of further enhancing the effectiveness of pharmacovigilance efforts, leading to safer and more reliable pharmaceutical products.

References

1. Terzano C, Conti V, Di Stefano F, Petroianni A, Ceccarelli D, Graziani E, et al. Comorbidity, hospitalization, and mortality in COPD: results from a longitudinal study. Lung. 2010;188:321-329.

   [Crossref] [Google Scholar] [PubMed]

2. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet. 2012;379(9823):1341-1351.

   [Crossref] [Google Scholar] [PubMed]

3. Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage. 2006;31(1):58-69.

   [Crossref] [Google Scholar] [PubMed]

4. Cheng JS, Huang WF, Lin KM, Shih YT. Characteristics associated with benzodiazepine usage in elderly outpatients in Taiwan. Int J Geriatr Psychiatry. 2008;23(6):618-624.

   [Crossref] [Google Scholar] [PubMed]

5. Light RW, Merrill EJ, Despars JA, Gordon GH, Mutalipassi LR. Prevalence of depression and anxiety in patients with COPD: relationship to functional capacity. Chest. 1985;87(1):35-38.

   [Crossref] [Google Scholar] [PubMed]

6. Kontopoulou K, Iosifidis E, Antoniadou E, Tasioudis P, Petinaki E, Malli E, et al. The clinical significance of carbapenem-resistant Klebsiella pneumoniae rectal colonization in critically ill patients: from colonization to bloodstream infection. J Med Microb. 2019; 68(3):326-35.

   [Crossref] [Google Scholar] [Pubmed]

7. Li Y, Shen H, Zhu C, Yu Y. Carbapenem-resistant Klebsiella pneumoniae infections among ICU admission patients in central China: Prevalence and prediction model. BioMed Res Int. 2019; 9767313.

   [Crossref] [Google Scholar] [Pubmed]

8. Forde C, Stierman B, Ramon-Pardo P, Dos Santos T, Singh N. Carbapenem-resistant Klebsiella pneumoniae in barbados: driving change in practice at the national level. PLoS One. 2017; 12(5):e0176779.

   [Crossref] [Google Scholar] [Pubmed]

9. Marsh JW, Mustapha MM, Griffith MP, Evans DR, Ezeonwuka C, Pasculle AW, et al. Evolution of outbreak-causing carbapenem-resistant Klebsiella pneumoniae ST258 at a tertiary care hospital over 8 years. MBio. 2019; 10(5):e01945-1919.

   [Crossref] [Google Scholar] [Pubmed]

10. Humphries RM, Yang S, Kim S, Muthusamy VR, Russell D, Trout AM, et al. Duodenoscope-related outbreak of a carbapenem-resistant klebsiella pneumoniae identified using advanced molecular diagnostics. Clin Infect Dis. 2017; 65(7):1159-1166.

    [Crossref] [Google Scholar] [Pubmed]